Abstract
The influence of Fc gamma receptor IIIA (FCGR3A) 158V/F polymorphisms on the response to rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is uncertain. Thus, a retrospective study and a meta-analysis were performed to examine the possible correlation between FCGR3A 158V/F polymorphism and the response rate of R-CHOP regimen in patients with newly diagnosed DLBCL. The genotypes of FCGR3A 158V/F in 164 newly diagnosed DLBCL patients treated with R-CHOP were determined in this retrospective study. Additionally, a meta-analysis of current and previously published studies was conducted. Overall response rate (complete and partial response, ORR) and complete response rate (CR) were evaluated. The results of our retrospective study showed lack of correlation between FCGR3A 158V/F polymorphism and ORR (p=0.78) or CR (p=0.76) with R-CHOP therapy. A meta-analysis of 731 cases also showed lack of significant association of ORR and CR in all genetic models with FCGR3A 158V/F polymorphism. In survival analysis, the homozygous F genotype correlated with a shorter progression-free survival than that of non-F/F genotype (p=0.05), this was significant for the non-GC subset of DLBCL (p=0.04), but no association was found between overall survival and FCGR3A 158V/F polymorphism. Further analysis with nonsuperiority test (p<0.0001) suggested that FCGR3A 158V/F polymorphism was not associated with better ORR or CR in newly diagnosed DLBCL patient treated with R-CHOP. No clear relationship was found between FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in patients with DLBCL.
Introduction
Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP) is the standard frontline therapy for diffuse large B-cell lymphoma (DLBCL) (Feugier et al., 2005; Habermann et al., 2006; Pfreundschuh et al., 2008). However, not all patients with DLBCL respond to R-CHOP therapy. The precise mechanisms of rituximab and its resistance have not been clearly defined. Antibody-dependent cellular cytotoxicity (ADCC) is one of the major mechanisms of rituximab activity (Cartron et al., 2004; Jazirehi and Bonavida, 2005). Fc gamma receptor IIIA (FCGR3A) is the major key factor of ADCC. Previous in vitro studies indicated that the level of ADCC activity depends on the genetic polymorphism of FCGR3A 158V/F (rs396991 G/T) (Koene et al., 1997). Recently, several studies reported the relationship of FCGR3A 158V/F polymorphism with response to R-CHOP in patients with DLBCL (Kim et al., 2006; Mitrovic et al., 2007; Zhang et al., 2010; Ahlgrimm et al., 2011; Fabisiewicz et al., 2011; Varoczy et al., 2012). The reported results appear to be controversial since two reported that this polymorphism is predictive for the response of R-CHOP in patients with DLBCL (Kim et al., 2006; Zhang et al., 2010), whereas the other four studies disagreed (Mitrovic et al., 2007; Ahlgrimm et al., 2011; Fabisiewicz et al., 2011; Varoczy et al., 2012).
We performed a retrospective analysis of this relationship in 164 patients with DLBCL who were treated with R-CHOP in our center. Further, we did a meta-analysis of published data to delineate this plausible association. We conclude that no clear relationship exists between FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in patients with DLBCL.
Patients, Materials, and Methods
Retrospective study
Patients
This clinical research protocol was approved by our Institutional Review Board (IRB) and by the Research and Ethical Committee of Peking University School of Oncology.
This study included 164 patients with CD20+ DLBCL confirmed by our Department of Pathology according to the World Health Organization classification. All patients received standard R-CHOP or R-CHOP-like chemotherapy regimen between June 2007 and December 2010 at Beijing Cancer Hospital, Peking University School of Oncology (Jin et al., 2012; Lin et al., 2013). R-CHOP-like regimen consists of R-CHOP and etopside or methotrexate (MTX). Among the 164 patients, 129 received frontline R-CHOP and were evaluable for clinical efficacy. Of the 129 patients, 31 patients received involved-field radiation. The response to R-CHOP therapy was evaluated after completion of 2–3 courses of therapy and 1–2 months after completion of all therapies. All responding patients were followed up every 3 months for the first year and every 6 months thereafter until progression.
FCGR3A gene polymorphism study
One single-nucleotide polymorphism (SNP) of FCGR3A gene was evaluated in the current study. Blood samples were obtained from all lymphoma patients before the initiation of therapy for genetic analysis. Genomic DNA was prepared from peripheral blood mononuclear cells using Blood Genomic DNA Extraction kit following the manufacturer's instructions (Bioteke Corporation).
The FCGR3A gene polymorphism was detected by polymerase chain reaction (PCR)–sequencing assay as previously described (Huang et al., 2013). The first PCR primers for the FCGR3A gene SNP at locus 158 were 5-ATA TTT ACA GAA TGG CAC AGG-3 and 5-GAC TTG GTA CCC AGG TTG AA-3[8], while the second PCR primers for the FCGR3A gene at locus 158 were 5-ATA TTT ACA GAA TGG CAC AGG-3 and 5-ATG CTG CAG AGT GAA TGA CAC-3, generating a 394-bp fragment. PCR was done on a thermocycler (Gene Cycler™; Bio-Rad) in a 30 μL reaction volume containing 30 ng genomic DNA. The PCR program for first-step amplification for the FCGR3A gene at locus 158 was as the following: denaturation at 94°C for 5 min, followed by 35 cycles of 94°C for 30 s, 56°C for 30 s, 72°C for 1 min 45 s, and the final elongation step at 72°C for 7 min. And second-step amplification for the FCGR3A gene at locus 158 was as follows: denaturation at 94°C for 5 min, followed by 35 cycles of 94°C for 30 s, 57°C for 30 s, 72°C for 45 s, and the final elongation step at 72°C for 7 min. Amplified products were analyzed by gel electrophoresis on 2% agarose gels. All fragments of the second-step amplification were purified with the AxyPrep DNA Gel Extraction kit according to the manufacturer's instructions (Axygen Sci, Inc.). Those purified products were sequenced using an ABI 3730XL Avant Genetic Analyzer (Applied Biosystems, Inc.). Finally, the sequences were analyzed with the software Seqman (DNASTAR, Inc.).
Definitions
Clinical responses were determined following the criteria formulated by International Working Group (Cheson et al., 1999) and as previously published (Chauchet et al., 2012; Jin et al., 2012; Lin et al., 2013).
Statistical analysis
The clinical characteristics and response rate were compared using χ2 test and Fisher's exact test. The association of the polymorphism with overall survival (OS) and progression-free survival (PFS) was analyzed using Kaplan–Meier plotting and the log-rank test. The prognostic factors were evaluated by the Cox regression model. Differences between groups were regarded as significant with a p<0.05. All tests of statistical significance were two-sided. The analysis was performed using the SPSS software package (v.16.0; SPSS).
Meta-analysis
Selection of studies for meta-analysis
We carefully searched Medline (through PubMed), ISI Web of Science databases, Cochran Library, Chinese Wanfang Data, and CNKI (China National Knowledge Infrastructure) before December 30, 2013, without language limitation. The search strategy was designed by two researchers and included the following terms: “diffuse large B-cell lymphoma” or “DLBCL” and “FCGR3A” or “Fcgamma receptor IIIA.” Further, hand searches of bibliographies in these studies and other published reviews were conducted. All of the identified records were examined independently by two reviewers.
Studies were considered eligible if the publications met all of the following criteria: (1) FCGR3A gene 158V/F (rs396991) polymorphism, (2) specified the histological subtype as DLBCL, (3) compared relationship of FCGR3A SNP and response to R-CHOP group, and (4) the genotype distribution of the studies had to be consistent with a Hardy–Weinberg equilibrium (HWE) (p>0.05). For the studies that investigated the same or subset populations, the studies with the most recent or larger sample size were included (Zhang et al., 2009, 2010). Studies were excluded for the reasons indicated in Figure 1 (following the PRISMA 2009 Flow Diagram www.Prisma-statement.org). As a result, a total of seven studies were included.
FIG. 1.
PRISMA 2009 Flow Diagram in our study.
Data extraction and quality assessment
The following information from each publication was carefully extracted by two investigators independently: the first author's last name, year of publication, country of study, median age (range), gender, stages, chemotherapy, response indicators, genotyping method, sample size, and genotype frequency.
To evaluate the quality of the included studies, we followed the checklist based on the Graphic Appraisal Tool for Epidemiological studies (GATE) (Jackson et al., 2006). The quality of each article was independently appraised by two reviewers and assigned a score. Each item was rated as +1 (well reported and reliable), 0 (unclear, insufficient detail provided), or −1 (poorly reported, not useful or reliable). The overall validity of each study was also rated by a similar system: +1 (most of the quality items were fulfilled), 0 (some criteria were not fulfilled), or −1 (few or none of the items were fulfilled) (Lau et al., 1997).
Statistical analyses
The meta-analysis was performed with Review Manager (v5.2; Oxford) and Stata statistical software (v.12.0; Stata Corp). The pooled odds ratios (ORs) and 95% confidence interval (CI) for the response rate associated with V/V allele compared with non-V/V allele of FCGR3A gene 158V/F polymorphisms were calculated for total subjects. A χ2-based Q test was performed to assess the study heterogeneity (Lau et al., 1997; Higgins et al., 2003). Following previously published methods, a fixed-effect model using the Mantel–Haenszel method was used to analyze the pooled data, p-value >0.1 and I2 value is <25% (Ma et al., 2012; Rafiyath et al., 2012; He et al., 2013). The significance of the pooled OR was determined by the Z test; a p-value of <0.05 was considered significant. Publication bias was investigated by Begg's funnel plot and the Egger's regression test (Egger et al., 1997).
The Power and Sample Size Program software was applied to calculate for power analysis (Dupont and Plummer, 1990), and the commonly observed relative risk (RR) of 1.10 was used to estimate risk, which represents a “weak” gene effect (Li et al., 2013).
An equivalence-based method in a nonsuperiority mode was applied to confirm the hypothesis of absence of association between FCGR3A gene 158V/F SNP and response rate to R-CHOP (Gourraud, 2011; Li et al., 2013).
Results
Retrospective study
Patient characteristics
The general features of the patients in this study are summarized in Table 1, including 81 women and 83 men. The median age at diagnosis was 53 years (range, 15–90 years). Eighty-nine (54%) patients were in stage III or IV, and 50 (30%) patients had intermediate-high or high International Prognostic Index (IPI) scores. Bone marrow was involved by lymphoma in six patients (4%) at diagnosis. R-CHOP followed by involved-field radiation was given to 31 (19%) patients. R-CHOP as a front-line regimen was administrated to all patients, and 129 patients were evaluable for clinical efficacy in this study. The median doses of rituximab delivered were six (range, 4–14), and a median of six cycles of chemotherapy was given (range, 2–8 cycles).
Table 1.
Patients' Characteristics and Their Correlations with FCGR3A Alleles
| Genotype | Genotype | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical parameters | No. | FF | FV | VV | pa | Clinical parameters | No. | FF | FV | VV | pa |
| Gender | Bulky mass | ||||||||||
| Male | 83 | 42 | 36 | 5 | 0.10 | ≥10 cm | 18 | 9 | 6 | 3 | 0.42 |
| Female | 81 | 49 | 23 | 9 | <10 cm | 146 | 82 | 53 | 11 | ||
| Age | Localized | ||||||||||
| ≤60 | 102 | 56 | 39 | 7 | 0.53 | Yes | 25 | 10 | 13 | 2 | 0.18 |
| >60 | 62 | 35 | 20 | 7 | No | 139 | 81 | 46 | 12 | ||
| B symptoms | No extra nodal | ||||||||||
| Positive | 62 | 33 | 19 | 10 | 0.02 | ≤1 | 122 | 63 | 48 | 11 | 0.23 |
| Negative | 102 | 58 | 40 | 4 | >1 | 42 | 33 | 9 | |||
| LDH | Incidence site | ||||||||||
| Positive | 77 | 47 | 23 | 7 | 0.31 | Lymph node | 93 | 54 | 32 | 7 | 0.72 |
| Negative | 87 | 44 | 36 | 7 | Extralymph | 71 | 37 | 27 | 7 | ||
| β2-MG | IPI | ||||||||||
| Positive | 49 | 29 | 14 | 6 | 0.29 | 0–2 | 114 | 61 | 44 | 9 | 0.56 |
| Negative | 106 | 55 | 43 | 8 | 3–5 | 50 | 30 | 15 | 5 | ||
| Stage | Molecular subtypes | ||||||||||
| I-II | 75 | 41 | 29 | 5 | 0.65 | GCB | 28 | 18 | 10 | 0 | 0.22 |
| III-IV | 89 | 50 | 30 | 9 | Non-GCB | 113 | 63 | 39 | 11 | ||
χ2 test.
LDH, lactate dehydrogenase level; MG, macroglobulin; IPI, international prognostic index; GCB, germinal center B cell.
FCGR3A 158V/F polymorphism
The frequency of the FCGR3A [158F] allele among all patients was 0.73, whereas the frequency of the FCGR3A [158V] allele was 0.27. Ninety-one patients (55%) were homozygous F, 14 patients (8%) were homozygous V, and 59 patients (36%) were heterozygous. The genotype distribution of DLBCL population enrolled in our study was in HWE with regard to the FCGR3A [158] polymorphism examined (p=0.32). There was no significant difference in the disease features between FCGR3A gene polymorphism groups (Table 1).
Clinical responses and FCGR3A 158V/F polymorphism
Among the 129 patients evaluable for response to R-CHOP, the ORR was 87.59% (113 of 129 patients) with a CR of 62.01% (80 of 129 patients), and a partial response rate of 25.58% (33 of 129 patients). As shown in Table 2, there is no statistical difference in CR rates in the FCGR3A V/V allele (60.00%) group compared with V/F (62.00%) and F/F allele (77.8%; p=0.76) groups. The difference in ORR was not significant in the FCGR3A V/V allele (85.71%) compared with V/F (90.00%) and F/F alleles (88.89%; p=0.78).
Table 2.
Clinical Response to R-CHOP Therapy According to FCGR3A Alleles
| FCGR3A genotype no.(%) | ||||
|---|---|---|---|---|
| Response | FF | FV | VV | p-Valuea |
| No. (N=129) | 70 | 50 | 9 | |
| CR | 42 (60.0) | 31 (62.0) | 7 (77.8) | 0.76 |
| PR | 18 (25.7) | 14 (28.0) | 1 (11.1) | |
| SD/PD | 10 (14.3) | 5 (10.0) | 1 (11.1) | |
| ORR (CR+PR) | 60 (85.7) | 45 (90.0) | 8 (88.9) | 0.78 |
χ2 test.
CR, complete response; ORR (CR+PR), overall response; PD, progressive disease; PR, partial response; SD, stable disease.
Survival analysis according to FCGR3A 158V/F polymorphism status
After a median follow-up of 524 days (range, 60–2073 days), 32 (25%) patients relapsed or progressed, and 18 (14%) died. Number of events in the survival analysis is summarized in Table 3. Seven patients participated in a clinical trial evaluating everolimus (RAD001) as maintenance therapy and were censored for PFS analysis. Seven patients were censored for lacking follow-up data on progression. The patients with homozygous F/F genotype had a median PFS of 426.5 days (range, 41–1275 days) versus 487 days (range, 50–1230 days) for V/V and V/F genotypes. This difference was borderline significant (p=0.05) (Supplementary Fig. S1; Supplementary Data are available online at www.liebertpub.com/dna). When patients were further subdivided into germinal center (GCB) and non-GCB lymphoma groups, the difference reached a statistical significance in non-GCB group (p=0.04) (Supplementary Fig. S2). Survival data were available for 129 patients. The OS was 532.5 days (range, 152–1364 days) for homozygous F/F patients, and 668 days (range, 152–1350 days) for V carriers (p=0.48, Supplementary Fig. S3). This difference was not statistically significant between GCB and non-GCB groups (data not shown).
Table 3.
Survival Analysis of DLBCL Subjects by FCGR3A Alleles
| Comparisons (no.) | Subtypes (no.) | FCGR3A 158V/F allele | Total no. | No. of event | Survival (%) | p-Valuea |
|---|---|---|---|---|---|---|
| Overall survival (129) | FF | 70 | 11 | 59 (84.3) | 0.48 | |
| VV+VF | 59 | 7 | 52 (88.1) | |||
| Progression-free survival (115) | FF | 62 | 22 | 40 (64.5) | 0.05 | |
| VV+VF | 53 | 10 | 43 (81.1) | |||
| GCB(25) | FF | 16 | 0 | 16 (100.0) | — | |
| VV+VF | 9 | 0 | 9 (100.0) | |||
| Non-GCB(78) | FF | 41 | 21 | 20 (48.8) | 0.04 | |
| VV+VF | 37 | 8 | 29 (78.4) |
Log rank (Mantel-COX) test.
DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B cell.
Multivariate analysis
A multivariate analysis was done to evaluate the effect of the following variables on OS and PFS: age (≤60 vs. >60 years), stage (stages 1, 2 vs. 3, 4), B symptoms (positive vs. negative), β2-microglobulin level (normal vs. abnormal), lactate dehydrogenase level (LDH) (normal vs. abnormal), IPI score (0–2 vs. 3–5), number of extranodal sites (≤1 site vs. ≥2 sites), bulky mass (≥10 cm vs. <10 cm), and Exon2[216] (homozygous C vs. T carriers). Among these, LDH (p=0.004, HR 6.21, 95% CI 1.78–21.65) was the only parameter as a poor prognostic factor.
Meta-analysis results
Characteristics of the studies and assessment of quality
The search identified 17 abstracts, of which 6 met the inclusion criteria (Table 4). Eleven were omitted because of the following reasons: (1) the article was a meeting abstract, (2) the data was already published in another article identified in the search, and (3) data did not include the response rate (Fig. 1).
Table 4.
Characteristics of Studies Included in the Meta-Analysis
| Genotype frequency | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Country | Diagnosis | Sample size | Median age years (range) | Gender (male/female) | Stages 3, 4 (%) | Chemotherapy cycle (range) | Evaluation criteria | Outcomes | Genotyping methods | FF | FV | VV |
| Kim et al. (2006) | Asian (Korea) | DLBCL | 113 | 60 (18–84) | 64/49 | 45 (40) | 6 (1–8) | International working group criteria 1999 | RR, PFS, and OS | PCR-RFLP | 6 | 54 | 53 |
| Mitrovic et al. (2007) | Caucasian (Croatia) | DLBCL | 58 | NR (18–84) | 37/21 | 34 (59) | NR | International working group criteria 1999 | RR, PFS, and OS | PCR-RFLP | 10 | 32 | 16 |
| Zhang et al. (2010) | Asian (China) | DLBCL | 34 | 42 (19–73) | NA | 18 (53) | 6 (4–8) | International working group criteria 1993 | RR and OS | PCR | 5 | 18 | 11 |
| Ahlgrimm et al. (2011) | Caucasian (German) | DLBCL | 263 | 68 (61–80) | 141/122 | 128 (49) | NR | International Working Group criteria 2008 | RR, PFS, and OS | Real-time PCR | 47 | 140 | 76 |
| Fabisiewicz et al. (2011) | Caucasian (Poland) | DLBCL | 87 | 57 (25–81) | 41/46 | 64 (74) | 6 (4–8) | International working group criteria 1999 | RR, PFS, and OS | Taqman SNR genotyping assays and sequencing | 37 | 35 | 15 |
| Varoczy et al. (2012) | Caucasian (Hungary) | DLBCL | 51 | 53.1 (19–83) | 19/32 | NR | NR (1–8) | NR | RR, PFS, and OS | Real-time PCR | 10 | 29 | 12 |
| Present study | Asian (China) | DLBCL | 129 | 53 (15–90) | 83/81 | 89 (69) | 6 (2–8) | International working group criteria 1999 | RR, PFS, and OS | PCR-sequencing | 70 | 50 | 9 |
NR, not reported; OS, overall survival; PCR-RFLP, polymerase chain reaction–restriction fragment length polymorphism; PFS, progression-free survival; RR, response rate.
So, the data for this analysis were obtained from seven studies (six that met the inclusion criteria plus the present study) (Kim et al., 2006; Mitrovic et al., 2007; Zhang et al., 2010; Ahlgrimm et al., 2011; Fabisiewicz et al., 2011; Varoczy et al., 2012).
Table 4 presents the main characteristics of these studies. There are three groups of Asians and four Caucasians. All except one of the seven studies scored the response to R-CHOP according to International Working Group criteria (Varoczy et al., 2012); most studies provided complete outcome data and full reporting of results. Most studies did not state whether the laboratory was blinded. Regarding the quality appraisal of the included studies, four were rated as +1 and 3 as 0 (Supplementary Table S1). All of the studied SNPs fulfilled the HWE (most studies used calculated HWE according to the original data.).
Association between polymorphism and response rate
Seven data sets were finally included in this meta-analysis with a total sample size of 731 patients. Table 5 summarizes the pooled RR estimates and the corresponding 95% CI of this meta-analysis. Data showed that individuals with the V/V allele did not have a significantly higher CR rate or ORR compared with FF, FV, or non-V/V (FF+FV). No significant associations with CR rate or ORR were found for FF allele compared with all genetic models (Table 5).
Table 5.
Summary of Pooled Risk Ratios with 95% Confidence Intervals and Heterogeneity for Various Genetic Contrasts Performed When Investigating the Association of FCGR3A 158V/F Polymorphism with the Response Rate of R-CHOP in DLBCL
| Pooled RR of 158V/F | Heterogeneity | ||||
|---|---|---|---|---|---|
| Contrast groups | Allele no. | p-Value | RR (95% CI) | I2 (%) | p-Value |
| CR vs. SD/PD | |||||
| FF vs. VV | 127/152 | 0.12 | 1.11 (0.97–1.26) | 37 | 0.15 |
| FF vs. FV | 127/268 | 0.28 | 0.95 (0.85–1.05) | 35 | 0.16 |
| FF vs. FV+VV | 127/420 | 0.20 | 0.99 (0.86–1.13) | 52 | 0.05 |
| VV vs. FV | 152/268 | 0.34 | 1.04 (0.96–1.12) | 0 | 0.83 |
| VV vs. FV+FF | 152/395 | 0.15 | 1.06 (0.98–1.14) | 0 | 0.58 |
| ORR vs. SD/PD | |||||
| FF vs. VV | 157/166 | 0.13 | 1.09 (0.97–1.23) | 42 | 0.11 |
| FF vs. FV | 157/305 | 0.26 | 0.95 (0.87–1.04) | 40 | 0.13 |
| FF vs. FV+VV | 157/481 | 0.17 | 0.95 (0.87–1.02) | 58 | 0.03 |
| VV vs. FV | 166/305 | 0.36 | 1.03 (0.96–1.11) | 0 | 0.83 |
| VV vs. FV+FF | 166/462 | 0.16 | 1.05 (0.98–1.13) | 0 | 0.54 |
The OS analysis according to the FCR3A 158V/F genotypes of these patients showed no difference in the published studies (Kim et al., 2006; Mitrovic et al., 2007; Zhang et al., 2010; Ahlgrimm et al., 2011; Fabisiewicz et al., 2011; Varoczy et al., 2012), except for a borderline significant association with PFS in our present study. Because the raw survival data were not available in studies included, the FCR3A 158V/F genotype comparisons for PFS analysis were not stratified for GCB and non-GCB subgroups in our meta-analysis.
Publication bias
We found no evidence of publication bias using the Begg's funnel plots and Egger's test for all genetic models of FCR3A 158V/F polymorphism (data not shown).
Power analysis
A post hoc power analysis on the total sample size used for the meta-analysis was calculated using the following parameters: 187 patients with V/V allele and 374 controls of non-V/V allele, two-tailed α=0.05, and for retrospective cohort study, prior data indicate that the response rate among controls is 0.84. Given the inconsistent relative risk of FCR3A 158V/F polymorphism for R-CHOP in DLBCL patients, we determined the commonly observed relative risk to be 1.10 in genetic association studies. The results showed in a power of 82% for ORR for the present sample size.
Equivalence-based test to confirm the nonassociation between 158V/F SNP and response to R-CHOP
Nonsuperiority mode was used to confirm the nonassociation between FCGR3A gene 158V/F SNP and response rate to R-CHOP. The null hypothesis of the test is that the frequency of 158V allele is greater by 3% compared with the frequency in controls. The specific 2% was set, since the lowest difference of 158V allele between ORR and SD/PD in seven independent populations was 2.3%. Thus, a 2% advantage in response group can be regarded as a fairly stringent cut-off.
Based on the just explained hypothesis, the nonsuperiority p-value was <0.0001, indicating the absence of association between 158V/F SNP and response rate to R-CHOP in DLBCL patients.
Discussion
Our retrospective study of the role of FCGR3A polymorphism in DLBCL is by far the largest for Chinese patients, and the results showed that there were no significant association between FCGR3A 158V/F polymorphism and ORR (p=0.78) or CR (p=0.76) with R-CHOP therapy. These results differed from those of two prior reports on Asian patients (Kim et al., 2006; Zhang et al., 2010). The two prior reports, however, had fewer patients included. Moreover, we conducted a meta-analysis of the data pooled from seven published reports to further delineate the predictive value of FCGR3A gene F158V polymorphism in DLBCL therapy. The results of meta-analysis of 731 cases agreed with our single-center data and confirmed that FCGR3A 158V/F polymorphism did not affect ORR and CR of R-CHOP therapy (Table 5).
Our patients revealed higher frequency of F allele than the V allele. This frequency distribution is not significantly different from that reported in Japanese cases (p>0.05) (Hirakawa et al., 2011), but is quite different from another two reports—one in a smaller sample of Chinese patients (34 patients, p=0.003) and one in Korean cases (p<0.001) (Kim et al., 2006; Zhang et al., 2010). Other specific factors, such as patient stratification, genotyping errors, and environmental exposure, may also contribute to this observed discrepancy (Gourraud, 2011).
In our retrospective study, we analyzed the survival data of our DLBCL patients. Although there was no difference in OS, patients carrying homozygous F genotype had a shorter PFS (p=0.05) (Table 3). When the patients were subdivided into GCB and non-GCB lymphoma groups, the inferior survival time was observed in the latter lymphoma group (p=0.04). Although not significant, as to PFS and/or event-free survival, a trend toward an unfavorable outcome for carriers of FCR3A 158F/F was reported in R-CHOP-treated patients in the German and Hungary studies (Ahlgrimm et al., 2011; Varoczy et al., 2012). According to this, the FCR3A 158V/F polymorphisms likely affect duration of response by altering the degree and depth of malignant B cell depletion. And the difference of depletion appears more prominent in non-GCB. Different mechanisms for anti-CD20-mediated depletion depending on the B-cell subpopulations may be one reason (Hamaguchi, 2009; Leandro, 2013). Ongoing studies need to explore the association of this SNP with survival in a larger population of DLBCL and verify it with laboratory experiment. Among clinical variables, only LDH was a poor prognostic factor (p=0.004, HR 6.21, 95% CI 1.78–21.65).
We have showed that our sample size has enough power to detect significance using relative risk corresponding to small effect size (relative risk=1.10). However, if we used the observed relative risk (1.05) in the meta-analysis, then the present sample size would only have 25.5% power of detecting significant association. The sample size would have to be increased to more than 811 cases and 1622 controls in order for the sample to have 80% power of detecting a significant association (α <0.05). Therefore, the sample size for the meta-analysis remains small, which is a significant limitation. To avoid such possible false-negative association from this study, equivalence-based method that minimizes the probability of observing a lack of association by chance was used. p-Value of the nonsuperiority test for FCGR3A 158V/F SNP was <0.0001, which strengthens the probability of nonassociation between FCGR3A polymorphism and R-CHOP response rate.
In conclusion, our retrospective study together with the meta-analysis demonstrated nonassociation between FCGR3A 158V/F gene polymorphism and response to frontline R-CHOP in DLBCL patients.
Author Contributions
Z.J. and S.Y.Q. designed the study and reviewed the final article. L.F. collected and analyzed the data for meta-analysis. D.H.R. performed and evaluated the experiments. J.X. and D.N. helped to perform the experiments. F.Z.Y. helped to collect the samples. H.Y. helped to perform meta-analysis. F.L., S.Y.Q., and D.H.R. wrote the article. L.F. and D.H.R. contributed equally to this work. All authors read and approved the final article.
Supplementary Material
Acknowledgments
The authors would like to thank Dr. Bin Su and Dr. Ming Li (State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, People's Republic of China) and Dr Lei Gao (Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, People's Republic of China) for their help with the power analysis and equivalence-based analysis. This study was supported by a grant from the National Science Foundation Committee (NSFC) of China (No. 30973484).
Disclosure Statement
The authors have no conflicts of interest.
References
- Ahlgrimm M., Pfreundschuh M., Kreuz M., Regitz E., Preuss K.D., and Bittenbring J. (2011). The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 118,4657–4662 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cartron G., Watier H., Golay J., and Solal-Celigny P. (2004). From the bench to the bedside: ways to improve rituximab efficacy. Blood 104,2635–2642 [DOI] [PubMed] [Google Scholar]
- Chauchet A., Michallet A.-S., Berger F., Bedgedjian I., Deconinck E., Sebban C., et al. (2012). Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol 5,27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. (1999). Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17,1244. [DOI] [PubMed] [Google Scholar]
- Dupont W.D., and Plummer W.D., Jr. (1990). Power and sample size calculations. A review and computer program. Control Clin Trials 11,116–128 [DOI] [PubMed] [Google Scholar]
- Egger M., Davey Smith G., Schneider M., and Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315,629–634 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fabisiewicz A., Paszkiewicz-Kozik E., Osowiecki M., Walewski J., and Siedlecki J.A. (2011). FcgammaRIIA and FcgammaRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 52,1604–1606 [DOI] [PubMed] [Google Scholar]
- Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Ferme C., et al. (2005). Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23,4117–4126 [DOI] [PubMed] [Google Scholar]
- Gourraud P.A. (2011). When is the absence of evidence, evidence of absence? Use of equivalence-based analyses in genetic epidemiology and a conclusion for the KIF1B rs10492972*C allelic association in multiple sclerosis. Genet Epidemiol 35,568–571 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., et al. (2006). Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24,3121–3127 [DOI] [PubMed] [Google Scholar]
- Hamaguchi Y. (2009). Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy. Nihon Rinsho Mwneke Gakkai Kaishi 32,29–34 [DOI] [PubMed] [Google Scholar]
- He M., Fan W., and Zhang X. (2013). Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol 6,80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. (2003). Measuring inconsistency in meta-analyses. BMJ 327,557–560 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hirakawa T., Yamaguchi H., Mitamura Y., Kosaka F., Dan K., and Inokuchi K. (2011). No racial difference in allele frequencies of FCGR3A gene F158V polymorphisms in diffuse large B-cell lymphoma. Eur J Haematol 86,180–181 [DOI] [PubMed] [Google Scholar]
- Huang T., Zhuge J., and Zhang W. (2013). Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomarker Res 1,3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jackson R., Ameratunga S., Broad J., Connor J., Lethaby A., Robb G., et al. (2006). The GATE frame: critical appraisal with pictures. Evid Based Nurs 9,68–71 [DOI] [PubMed] [Google Scholar]
- Jazirehi A.R., and Bonavida B. (2005). Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24,2121–2143 [DOI] [PubMed] [Google Scholar]
- Jin X., Ding H., Ding N., Fu Z., Song Y., and Zhu J. (2012). Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. J Hematol Oncol 5,51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kim D.H., Jung H.D., Kim J.G., Lee J.J., Yang D.H., Park Y.H., et al. (2006). FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108,2720–2725 [DOI] [PubMed] [Google Scholar]
- Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E., and de Haas M. (1997). Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90,1109–1114 [PubMed] [Google Scholar]
- Lau J., Ioannidis J.P., and Schmid C.H. (1997). Quantitative synthesis in systematic reviews. Ann Intern Med 127,820–826 [DOI] [PubMed] [Google Scholar]
- Leandro M.J. (2013). B-cell subpopulations in humans and their diff erential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 15(Suppl 1),S3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li M., Zhang H., Luo X.J., Gao L., Qi X.B., Gourraud P.A., et al. (2013). Meta-analysis indicates that the European GWAS-identified risk SNP rs1344706 within ZNF804A is not associated with schizophrenia in Han Chinese population. PLoS One 8,e65780. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lin N., Song Y., Zheng W., Tu M., Xie Y., Wang X., et al. (2013). A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol 6,44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ma Y., Xu Y.-C., Tang L., Zhang Z., Wang J., and Wang H.-X. (2012). Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 1,11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitrovic Z., Aurer I., Radman I., Ajdukovic R., Sertic J., and Labar B. (2007). FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 92,998–999 [DOI] [PubMed] [Google Scholar]
- Pfreundschuh M., Schubert J., Ziepert M., Schmits R., Mohren M., Lengfelder E., et al. (2008). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9,105–116 [DOI] [PubMed] [Google Scholar]
- Rafiyath S., Rasul M., Lee B., Wei G., Lamba G., and Liu D. (2012). Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 1,10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Varoczy L., Zilahi E., Gyetvai A., Kajtar B., Gergely L., Sipka S., et al. (2012). Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol Res 18,43–48 [DOI] [PubMed] [Google Scholar]
- Zhang W., Wang X., Duan M.H., Li J., and Zhou D.B. (2009). [Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study]. Zhonghua Yi Xue Za Zhi 89,400–402 [PubMed] [Google Scholar]
- Zhang W., Wang X., Li J., Duan M.H., and Zhou D.B. (2010). Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin Med J (Engl) 123,198–202 [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.

